Hepatocellular carcinoma and strongyloides infection with portal vein thrombosis

Abstract

More than 80% of the primary liver cancers are hepatocellular carcinomas (HCC) and these tumors occur in livers that are cirrhotic due to, for example, chronic hepatitis B (HBV) or C (HCV) viral infections.

We report a case of a 64-year-old Egyptian male who was admitted to our hospital with fever of unknown origin and elevated liver enzymes. He is known with HCV and multifocal HCC. He was treated for the HCC with a partial left liver resection and radiofrequency ablation (RFA), recently. Eventually there appeared to be an underlying strongyloides infection which causes portal vein thrombosis with general malaise, elevated liver enzymes and ascites. After treatment of the strongyloides infection his laboratory results normalized and his symptoms disappeared.

Keywords: strongyloides infection, portal vein thrombosis, HCC

Case report

A few years ago 64-year-old Egyptian male was admitted to our gastro-enterology department because of fever. He is known with HCV and hepatocellular carcinoma for which he was operated on in 2008. This operation enhanced a partial left liver resection, but revealed to be irradical. He received RFA additionally. Now he presented himself with ongoing fever, antibiotics had no effect.

Laboratory showed elevated liver enzymes, especially cholestatic enzymes (AF en GGT) and elevated alpha-fetoprotein. Ultrasound en X-rays showed no abnormalities. During his stay in the hospital he deteriorates and developed ascites. And additional CT scan revealed a portal vein thrombosis (Figure 2). We could not find any other explanation for his complaints than recidive tumor with fever due to tumor necrosis. He was discharged from the hospital after 2 weeks and would be followed up on the outpatient clinic. He should receive palliative chemotherapy. Than in the outpatient clinic the serology of strongyloides and schistosomiasis became positive. The schistosomiasis infection is chronic. He was treated for the strongyloides infection with ivermectine (one dose) and remarkably his liver enzymes normalized. The ascites disappeared and he had no fever anymore. Also the alpha-fetoprotein deteriorated (Figure 1). The tumor was not progressive for a few years without any therapy.

Discussion

In Egypt, schistosomiasis (mansoni) was the major cause of liver disease. From 1950s until the 1980s, the Egyptian Ministry of Health undertook large control campaigns using the standard treatment for schistosomiasis as a community-wide therapy.

When in the 1990s the diagnostic serology became available HCV-infection became the dominant cause of chronic liver disease in Egypt. Studies showed that co-infections of HCV with schistosomiasis caused more severe liver disease. Patients with HCV and schistosoma infection have a higher risk of cirrhosis and HCC. The influence of a strongyloides infection has not been clarified yet.

The combination of schistosomiasis and HCC has been identified as an adverse prognostic factor. But for the strongyloides infection this has not been found. There are a few case reports published about biliary strongyloides infection, but only one with also portal vein thrombosis.

In this case the tumor marker deteriorates after treatment of the strongyloides infection. The treatment seems to have a positive effect on the tumor. We suspect that the strongyloides larvae were situated in the bile ducts and lead to cholestasis and inflammation, which explains the fever and so leading to portal vein thrombosis. The portal vein thrombosis disappeared after treatment of the strongyloides infection and all of the patient’s symptoms (Figure 3).
Conclusion

This is a rare case of cholestasis and portal vein thrombosis associated with strongyloides infection and HCC. This case highlights the challenges of treatment of HCC with diagnosing underlying infections. In patient with suspected geographic exposure consider infections like strongyloidiasis.

Acknowledgements

None.

Conflict of interest

Author declares that there is no conflict of interest.

References


